Document:

EX-10.1

EXECUTION COPY

SUPPLY AGREEMENT

This Agreement is effective as of May 1, 2008 and is made by and between Genta Incorporated, a
corporation of the State of Delaware, with an address at 200 Connell Drive, Berkeley Heights, New
Jersey 07922 (together with its Affiliates, “Customer”) and Avecia Biotechnology, a corporation of
the State of Delaware, with an address at 125 Fortune Boulevard, Milford, Massachusetts 017567
(“Avecia”). Customer and Avecia are sometimes referred to herein individually as a “Party” or
collectively as “Parties”.

WHEREAS, Avecia has knowledge and experience with regard to the GMP manufacture of oligonucleotides
with significant expertise in process technologies, research and development and process scale-up;

WHEREAS, Customer conducts research and development in relation to certain oligonucleotides with a
view to conducting clinical trials and seeking registration of the oligonucleotides in drug
products for the treatment of human diseases;

WHEREAS, Customer has an oligonucleotide compound, identified by the trademark ”Genasense,” which
is currently in Phase 3 clinical trials; and

WHEREAS, Customer and Avecia desire to enter into this Agreement to set forth the terms and
conditions upon which Avecia will supply certain of Customer’s requirements for API.

NOW, THEREFORE, intending to be legally bound, it is hereby agreed as follows:

1. Definitions.

“Affiliate” means any person, organization, corporation or other business entity, controlling,
controlled by or under common control with Customer.

“Agreement Year” means any period of twelve consecutive calendar months beginning with the first
full calendar month following the Effective Date.

“Applicable Laws” means applicable laws and regulations of the United States of America, including
all such federal, state and local laws, rules, regulations and ordinances.

“Customer Partner” means any third party to whom Customer has granted the right to distribute,
market or sell API (or any drug product which contains API).

“Confidential Information” means any technical, business, financial and other commercial
information of a confidential nature disclosed (whether disclosed in writing, orally, by way of
sample or by any other means and whether directly or indirectly) by either Party (the “Disclosing
Party”) to the other Party (the “Receiving Party”).

“Current Process” means the process validated by Avecia in 2003 for the manufacture of API.

“Delivery” or “Delivered” as used in Sections 7 and 10 means ex-works Avecia’s facility located in
Milford, MA.

 

 

EXECUTION COPY

“Effective Date” means the date of this Agreement.

“Facility” means Avecia’s cGMP facility located in Milford, MA, which currently consists of the
facilities designated as M1 and M2.

“cGMP” means current good manufacturing practice and standards as provided for (and as amended from
time to time) in the European Community Directive 91/356/EEC (Principles and guidelines of good
manufacturing practice for medicinal products) and the Current Good Manufacturing Practice
Regulations to the US Code of Federal Regulations, Title 21 (21 CFR 210 and 211) in relation to the
production of pharmaceutical intermediates and active pharmaceutical ingredients, as interpreted by
ICH Harmonized Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients, Q7, and subject to any arrangement, additions or clarifications agreed from time to
time between the Parties in the Quality Agreement.

“FDA” means the U.S. Food and Drug Administration, or any successor entity thereto or foreign
counterpart thereof.

“Governmental Authority” means any (1) nation, state, county, city, town, village, district or
other jurisdiction of any nature, (2) federal, state, local, municipal, foreign or other
government, (3) governmental or quasi-governmental authority of any nature (including any
governmental agency, branch, department, official or entity and any court or other tribunal,
including an arbitral tribunal), (4) multi-national organization or body, or (5) body exercising,
or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory
or taxing power of any nature.

“Independent Intellectual Property” shall have the meaning set forth in Section 13.

“Intellectual Property” means patents, patent applications, all provisional, divisional,
continuations, renewals, continuations in part, reexaminations, patents of addition, supplementary
protection certificates, extensions, letters of patent, registration or confirmation patents and
reissues with respect to any patents described in the foregoing clauses, any know how, trade
secrets, data, technology and technical information.

“Latent Defect” means an impurity in API caused by Avecia, other than an impurity which is an
intrinsic feature of API as produced by Avecia and present in numerous historic batches, which
would not be expected by Customer to be in such API, either by type or degree of impurity, and
which is not known to Customer or not readily discoverable by Customer at the time of delivery of
such API, using commercially reasonable inspection procedures.

“New Process” means process changes to the Current Process as contemplated in Section 3 and
Appendix 3.

“New Process Strategy” is the strategy for implementing a New Process as set forth in Appendix 3.

“New Process Validation” is the * by * of * of API produced in accordance with the New Process,
with the * being *.

2

 

EXECUTION COPY

“PAI” means “Pre Approval Inspection” which is the formal inspection of the Facility by a
Regulatory Authority for the purpose of approving the Facility for manufacture of commercial
quantities of API.

“API” means * that certain * oligonucleotide consisting of * with the sequence and chemical
structure set forth in Appendix 1, and currently referred to under the trademark
“Genasense.”

“API Requirements” means conformance with (a) cGMP, (b) API Specifications, (c) the current
validated process and (d) the Quality Agreement.

“API Release Date” means, with respect to any API sold by Avecia to Customer hereunder, (i) the
Avecia QA release date, if Avecia is responsible for all API release testing; or otherwise (ii) the
date of the completion of manufacturing and sign off by Avecia QA on the executed batch records and
the analytical report for all API release testing under Avecia control.

“API Specifications” means the specifications for the API as agreed and attached hereto as Appendix
4, as may be modified from time to time by the Parties.

“Quality Agreement” means the document agreed to by the Parties in the form attached hereto as
Appendix 5, as amended, supplemented or restated from time to time.

“Recall” shall have the meaning set forth in Section 18.6.

“Regulatory Authority” means the FDA or any court, tribunal, arbitrator, agency, commission,
official or other instrumentality of any federal, state, county, city or other political
subdivision, domestic or foreign, that performs a function for such political subdivision similar
to the function performed by the FDA for the United States with regard to the approval, licensing,
registration or authorization to test, manufacture, promote, market, distribute, use, store,
import, transport or sell a product in the defined territory or political subdivisions.

“Regulatory Authority Approval” means the first marketing approval by any Regulatory Authority for
the drug product containing API.

“Regulatory Requirements” means (i) any and all permits, licenses, filings and certifications
required by the US Food and Drug Administration (FDA), US Occupational Safety and Health
Administration (OSHA), US Environmental Protection Agency (EPA), The International Conference of
Harmonization Q7 (ICH Q7), The United States Pharmacopeia, (USP), The European Pharmacopeia (EP),
the European Medicines Agency (EMEA), and compliance with the cGMP of the FDA, ICH Q7, USP, EP and
EMEA, applicable to any manufacturing or processing activities hereunder or facilities at which any
of the manufacturing or processing activities hereunder are performed, and (ii) any Laws, rules,
guidelines, regulations, and standards of any governmental authority within the United States
(including, without limitation, EPA, OSHA, the Drug Enforcement Administration (DEA) and state and
local authorities), that apply to any manufacturing or processing activities hereunder or the
Facility or other facilities at which any of the manufacturing or processing activities hereunder
are performed.

“Requalification Plan” means the plan * , which describes * API using the Current Process at the
Facility.

3

 

EXECUTION COPY

“Rolling Forecast” shall have the meaning set forth in Section 6.2.

“Seizure” shall have the meaning set forth in Section 18.6.

“Shelf Life” means, with respect to particular quantities of API, the total time from date of such
API’s manufacture (such date of manufacture determined by reference to Avecia’s approved master
batch records) until the latest point in time at which such API’s conformance with API
Specifications can, in consideration of the passage of time, continue to be assured.

“Special Mechanism” shall have the meaning set forth in Section 4.2.

“Waste” shall mean any “hazardous substance” and/or “hazardous material” as provided under the
Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), any “hazardous
waste” as provided under the Resource Conservation and Recovery Act (RCRA), and/or any other waste
material, pollutant and/or contaminant of any kind including, without limitation, any routine
process waste or any by-product arising from any activities conducted pursuant to this Agreement.

2. Residual Commitments.

Within * of issuance of * will reimburse * for those materials * and * in accordance with the * in
the * of * that * has already * so the * has been * will continue to * where * and if the * the
benefit will be *. Other than a maximum liability of *owed by * as expressly set forth above,
neither Party shall owe the other Party any consideration or compensation for anything arising
prior to the Effective Date.

3. Current Process; New Process Implementation; Other Process Improvements.

	3.1	 	The initial pricing, campaign size and capacity availability for API formulated for this
Agreement are based upon the Current Process. In anticipation of the possibility for
significant beneficial changes to the Current Process, the Parties have developed a strategy
for implementing a New Process, which strategy is attached hereto as Appendix 3 (the “New
Process Strategy”). The New Process Strategy establishes *: (a) definition and demonstration
of the New Process (*); (b) investigation of the New Process * and * for the New Process * ;
and (c) New Process Validation *. The Parties shall verify that the New Process Strategy
complies with all Regulatory Requirements prior to its implementation.
	 
	3.2	 	In the event that the Parties agree to implement the New Process Strategy, Customer shall
make the following payments to Avecia: * agree to * the * agreement to *; and * following *of
*.
	 
	3.3	 	Other improvements to the Current Process not constituting a New Process and improvements to
the New Process after implementation of the New Process shall be implemented consistent with
the provisions of the Quality Agreement, with the

4

 

EXECUTION COPY

	 	 	assumption that the *. Prior to moving forward with any such proposed improvement, the * shall
agree on the *to be so *, it being * that such * would *, * of * and *. * which would not *
the * any * and * with necessary *. At Customer’s request, Avecia shall provide to Customer
detailed documentation sufficient * relating to any such improvement.

	3.4	 	The costs and benefits associated with any process improvements or changes which do not
require the approval of Customer under the Quality Agreement *.

4. Capacity; Capital or Other Investment.

	4.1	 	As of the Effective Date, Avecia has at the Facility installed equipment and assets with the
technical capability to produce API at the rate of * using the Current Process, which could be
increased to * with the implementation of the New Process (the “Facility Capacity”). * for
the * is * by the * for the * for * (the “Available Capacity”. The Available Capacity as of
the Effective Date is a maximum rate of *. If an increase in Available Capacity is required by
Customer forecasts, the Available Capacity shall be increased by Avecia to: the * of * during
the * the * after the * and *; the * during the * the *; the * thereafter. In the event of the
implementation of the New Process, the applicable Available Capacity would be * under the
Current Process.
	 
	4.2	 	In the event that Customer anticipates that its requirements for API will be in excess of the
Available Capacity set forth in Section 4.1, Avecia and Customer will work together, in good
faith, to agree on special mechanisms to accommodate such excess requirements. Such “Special
Mechanisms” might include, among other things, * in * and *. Special Mechanisms might *, among
other things*, and * to * and * to * and *. This Section 4.2 is intended, simply, to indicate
the good faith intention of the Parties to seek solutions to the possible changing
circumstances of Customer resulting in a need for API in excess of Avecia’s ability to supply.
For the avoidance of doubt, if Customer’s requirements fall within the Available Capacity
pursuant to Section 4.1, then no Special Mechanisms will apply * or * by *.

5. Term.

This Agreement shall take effect as of the Effective Date and shall remain in effect until the date
which is the earlier of (i) December 31, 2017 and (ii) the seventh anniversary of the date of
Regulatory Authority Approval (the “Initial Term”). Either Party may terminate this Agreement as of
the end of the Initial Term upon the giving of at least two (2) years prior written notice to the
non-terminating Party; provided that such notice must be given during the month of *; provided,
further, that the first time either Party may give such two (2) year notice is the date which is *
and *. In the absence of such notice, this Agreement shall continue in effect thereafter on a *
basis, with either Party having the right thereafter to terminate this Agreement upon the giving of
at least two (2) years prior written notice to the non-terminating Party.

5

 

EXECUTION COPY

6. Sale and Purchase; Forecasts; Minimum Order Size.

	6.1	 	During the term of this Agreement, Avecia shall sell and Customer shall purchase, and
Customer shall cause Customer’s Affiliates and Customer Partners to purchase, * of the
combined global requirements of Customer and such Affiliates and Customer Partners of API
during the term of this Agreement; provided, however, that, during any single Agreement Year,
Avecia shall sell and Customer shall purchase, and, if applicable, shall cause Customer’s
Affiliates and Customer Partners to purchase, (i) when the Rolling Forecast for such Agreement
Year is * of API, * of the global requirements of Customer and its Affiliates and Customer
Partners and (ii) when such Rolling Forecast is * a * of such requirements.
	 
	6.2	 	Within the first * of each * during the term of this Agreement, Customer shall provide to
Avecia a written forecast of the requirement for API of Customer (and, if applicable, of its
Affiliates and Customer Partners) during such * and the next succeeding * (the “Rolling
Forecast”). The forecasted quantity with respect to the * of each Rolling Forecast shall
constitute a firm commitment by Avecia to sell and Customer (and, if applicable, Customer
shall cause its Affiliates and Customer Partners) to purchase such forecasted quantity. The
forecasted quantity with respect to the * of such Rolling Forecast shall be a firm commitment
by Avecia to sell and Customer (and, if applicable, Customer shall cause its Affiliates and
Customer Partners) to purchase * up to * of such forecasted quantity. The forecasted quantity
with respect to the * of the Rolling Forecast shall be an indicative quantity with no
commitment on either Avecia or Customer.
	 
	6.3	 	Upon either Party’s request, the Parties will work together, in good faith, to permit Avecia
to increase the Available Capacity and, if applicable, agree upon a Special Mechanism.
Notwithstanding any provision of this Section 6, in no event shall Avecia be required to
supply API under this Agreement in an amount greater than the Available Capacity (unless the
Parties have agreed to increase the Available Capacity using a Special Mechanism pursuant to
Section 4.2, in which case the Parties will work together, in good faith, to permit Avecia to
increase the Available Capacity). If Avecia has not increased the Available Capacity,
Customer may purchase its API requirements in excess of the Available Capacity from a third
party until Avecia can meet such requirements and such purchases shall count towards
Customer’s minimum purchase requirements referred to in this Section 6; provided, however,
that, if Customer fails to negotiate in good faith, notwithstanding Avecia’s willingness to do
so, a Special Mechanism to increase the Available Capacity, any such purchases by Customer of
API from a third party shall not count towards Customer’s minimum purchase requirements
referred to in this Section 6.
	 
	6.4	 	Customer shall order API in quantities of at least *, provided that Customer may request *
of less than * and the price of such * shall be determined through good faith negotiation of
the Parties.
	 
	6.5	 	No Rolling Forecasts will be issued prior to Regulatory Authority Approval. The first Rolling
Forecast following Regulatory Authority Approval will be * in *. Avecia is

6

 

EXECUTION COPY

	 	 	allowed complete discretion to bring forward the timing of the * forecast in the * period to
any point within the *period of the first Rolling Forecast.

	6.6	 	If due to unusual or unanticipated circumstances, Customer has a requirement for API prior to
Regulatory Authority Approval, the Parties shall work together, in good faith, to fulfill and
otherwise accommodate such requirement.

7. Delivery; Title; Invoices; Payment Terms.

	7.1	 	API will be Delivered ex-works, the Facility. Notwithstanding any actions taken by Avecia on
behalf of Customer as hereinafter set forth in this Section 7, title and risk of loss in the
API shall pass to Customer on the earlier of (i) transfer at the Facility to Customer’s
designated agent or carrier and (ii) Avecia’s placement of such API in its cGMP storage area
at the Facility at Customer’s request.
	 
	7.2	 	Avecia shall arrange, on behalf of Customer, for the shipment of API to the location as
stated on the relevant purchase order. Avecia shall package API in a manner consistent with
good commercial practices, validated shipping procedures that comply with Regulatory
Requirements (including, without limitation, shipment in approved containers), and any
agreed-upon shipping specifications and the Quality Agreement.
	 
	7.3	 	Subject to the proviso to this Section 7.3, if Avecia Delivers any portion of API later than
the date of Delivery set out in the relevant purchase order then:
	 
	 	 	7.3.1  * shall be made with respect to * that is * than *;
	 
	 	 	7.3.2  * shall be made with respect to * that is *than * ;
	 
	 	 	7.3.3  * shall be made with respect to * that is *; that * such * shall be applicable to
the extent that any such * or * is *.
	 
	7.4	 	Avecia shall seek, in good faith, to make Delivery of amounts ordered by Customer in each
purchase order within * agreed to by the Parties in such purchase order. Avecia shall promptly
notify Customer of any occurrence expected to inhibit Avecia’s ability to provide on-time
Delivery of API meeting the terms and conditions of this Agreement. In addition, Avecia shall
promptly inform Customer of any notice, written or oral, received from any of its
subcontractors regarding a possible shortage or inability to obtain or supply API raw
materials or any components or materials used in the manufacture of API.
	 
	7.5	 	To the extent that Customer obtains quantities of API from an alternative source as a result
of a delay of *, then Customer shall be * identified in* to the extent that and for so long as
* as a result of the delay, * in such * herein.
	 
	7.6	 	Until Customer, its Affiliates and Customer Partners shall have purchased an aggregate of *
of API pursuant to this Agreement, Avecia shall issue invoices for API *of the API Release
Date for such API, as estimated by Avecia, and Customer shall pay, or arrange to have paid, to
Avecia: (i) * of the amount due under each such invoice by no later than * after Customer’s
receipt of such invoice and (ii) the remaining * of such amount by * after such API Release
Date. After Customer, its Affiliates and Customer Partners shall have purchased an *of API
pursuant to this Agreement, Avecia shall issue invoices for API on the API Release Date for
such API and Customer shall pay, or arrange to have paid, to Avecia *of the amount due under
each such invoice by no later than * after such API Release Date. If Avecia is not

7

 

EXECUTION COPY

	 	 	responsible for all API release testing, then the invoicing point will be the completion of
manufacturing and sign off by Avecia QA on the executed batch records and the analytical report
for all API release testing under Avecia’s control.

	7.7	 	In addition to the supply of API as contemplated hereunder, the Parties may develop and agree
to documents, each entitled a scope of work, setting forth the terms and conditions pursuant
to which Avecia would undertake for Customer development work or other service projects coming
within the terms of this Agreement (such as, for example, service projects related to the
matters set forth in Sections 17.7 and 17.8). Changes to any such scope of work shall be
agreed to in writing between the Parties. Invoices for services under any such scope of work
will be issued as follows: * in the *for such * on agreement to the scope of work; * for the
*. Customer on completion of the services under such scope of work. Unless otherwise stated
in the scope of work, “completion” will be defined as delivery of the draft report. Customer
shall pay such invoices within * of Customer’s receipt of any such invoice.

8. Exclusivity.

During * of this *, neither Avecia nor its Affiliates shall * or *or *of *. In the event that *
for * than the *of this * or *or * of *, for a * the * of the * of this *or the *. In the event
that * for * other than * of this * shall not be subject to the * of this * the * of *, but *of
this * shall continue in effect for a *the *of the * or the *. For clarity, the foregoing *.

9. Price.

	9.1	 	The price for API shall be determined in accordance with Appendix 2.
	 
	9.2	 	The price for API hereunder excludes any applicable sales, use, consumption, value added or
excise taxes, duties, tariffs and other similar assessments which may be imposed by any
Governmental Authority as a result of the sale of API hereunder. The Parties shall cooperate
and take any reasonable steps to reduce or eliminate such charges.

8

 

EXECUTION COPY

10. Acceptance of API.

	10.1	 	Within * of Delivery of API to Customer and except in the case of a Latent Defect, Customer
shall notify Avecia of any claim for shortage of API or that all or some of such API does not
meet API Requirements. In the absence of such notification, such API shall be deemed accepted
by Customer as complete and in accordance with API Requirements. In the event of a Latent
Defect, Customer shall have * from the earlier of (i) the date that Customer becomes aware of
such Latent Defect, (ii) the date that the applicable API is used by Customer (or its
Affiliate or Customer Partner, if applicable) in the manufacture of its drug product and (iii)
* after the API Release Date of the applicable API to notify Avecia of any claim with respect
thereto. In the absence of such notification, such API shall be deemed accepted by Customer as
in accordance with API Requirements even as to Latent Defects.
	 
	10.2	 	If Customer notifies Avecia in accordance with the provisions of Section 10.1 that API does
not conform to API Requirements or that the amount of API is less than the amount set forth in
the applicable invoice, Customer shall advise Avecia of the manner in which API does not
conform to API Requirements or shall document the shortage. In the event that Avecia accepts
such determination, Avecia shall, at Customer’s option, process free of charge sufficient API
or reimburse the price to Customer, to make up such shortage or replace defective API and
shall dispose of the defective API at Avecia’s cost.
	 
	10.3	 	If a dispute arises between the Parties as to any failure of API to meet API Requirements
which dispute is not resolved by the Parties within * of notice to Avecia as set forth in
Section 10.1, either Party shall be entitled to require that the matter in dispute be referred
to an independent laboratory or other appropriate expert nominated by agreement of the
Parties. Such referral shall be solely for the purpose of establishing whether or not there is
any failure of the relevant API to meet API Requirements. The decision of such independent
laboratory or expert shall be binding upon the Parties, and the Party against which the
decision is made shall be responsible for the costs of such independent laboratory or expert.
If the decision shows that Avecia failed to supply API in accordance with API Requirements,
then Avecia shall process free of charge sufficient API to replace the defective API and shall
dispose of the defective API at its own cost.
	 
	10.4	 	All API supplied to Customer shall at the time of Delivery have the longest remaining Shelf
Life reasonably practicable, but in any event a minimum of (i)* if the total Shelf Life from
the date of manufacture is equal to or greater than * and (ii) * if the total Shelf Life from
the date of manufacture is equal to or greater than* ; provided, however, that Avecia shall be
permitted to supply API with shorter Shelf Life on a case-by-case basis where Customer so
agrees in writing in advance of the shipment of such API.

9

 

EXECUTION COPY

11. Representations and Warranties.

	11.1	 	Avecia represents and warrants to Customer as follows:

	 	11.1.1	 	Avecia is a corporation validly existing and in good standing under the laws of the
State of Delaware, with the power to own all of its properties and assets and to carry on
its business as it is currently being conducted.
	 
	 	11.1.2	 	Avecia has the power to execute and deliver this Agreement and to perform its
obligations under this Agreement.
	 
	 	11.1.3	 	Avecia has obtained all necessary consents and authorizations to execute and deliver
this Agreement and to perform its obligations under this Agreement, and no other corporate
proceedings of Avecia or third party consents are necessary with respect thereto.
	 
	 	11.1.4	 	Avecia shall handle, accumulate, label, package, store, transport and dispose of all
Wastes generated through performance of the manufacturing and processing activities
hereunder in accordance with all Regulatory Requirements.
	 
	 	11.1.5	 	All API conforms to and is produced in accordance with API Requirements.
	 
	 	11.1.6	 	Avecia has, and will remain in material compliance with, all Applicable Laws, including
permits, licenses and other authorizations (the “Permits”) which are required under USA
federal, state and local laws, rules and regulations applicable to the manufacture of API.
	 
	 	11.1.7	 	No person performing services on behalf of Avecia under this Agreement has been debarred
under Section 306 of the United States Federal Food, Drug and Cosmetic Act nor otherwise
(i) disqualified or debarred by the FDA or any other Regulatory Authority for any purpose
pursuant to 21 U.S.C. § 355a or any foreign counterparts thereof; or (ii) charged with or
convicted under United States federal law, or foreign counterparts thereof, for conduct
relating to the development or approval of, or otherwise relating to the regulation of,
any drug product under the Generic Drug Enforcement Act of 1992 or any other relevant
statute, law or regulation.
	 
	 	11.1.8	 	Manufacture of API will be performed consistent with standards then customary in the
oligonucleotide and API industry, and, in any event, with at least the degree of care and
quality that Avecia uses to perform similar activities for other parties.
	 
	 	11.1.9	 	To the best of Avecia’s knowledge, Avecia’s manufacture of API in the performance of
this Agreement will not infringe the Intellectual Property or other rights of third
parties.
	 
	 	11.1.10	 	API manufactured using the New Process (i) will be of a quality equal to or better than
that of API manufactured using the Current Process, (ii) will have no new impurities, as
determined using the same analytical methods and (iii) will * than * the *.

	11.2	 	Customer represents and warrants to Avecia that (i) Customer is a corporation validly
existing and in good standing under the laws of the State of Delaware, with the power to own
all of its properties and assets and to carry on its business as currently being conducted,
(ii) Customer has the power to execute and deliver this Agreement and to perform its
obligations under this Agreement, (iii) Customer has

10

 

EXECUTION COPY

	 	 	obtained all necessary consents and authorizations to execute and deliver this Agreement and to
perform its obligations under this Agreement, and no other corporate proceedings of Customer or
third party consents are necessary with respect thereto, (iv) Customer has all rights necessary
to permit Avecia to manufacture API as contemplated in this Agreement and (v), to the best of
Customer’s knowledge, Avecia’s use of Customer’s Intellectual Property in the performance of
this Agreement will not infringe the Intellectual Property or other rights of third parties.

	11.3	 	EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY WARRANTY OF ANY KIND, EXPRESS,
IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. AVECIA
EXPRESSLY DISCLAIMS ANY WARRANTY OF MERCHANTABILITY OR FITNESS OF API FOR ANY PARTICULAR
PURPOSE.

12. Indemnification; Remedies; Limitation of Liability.

	12.1	 	Avecia shall indemnify and hold Customer harmless from all losses, liabilities, damages and
expense (including reasonable attorneys’ fees and costs) incurred as a result of any claim,
demand, action or other proceeding by a third party to the extent caused by (i) any breach by
Avecia of the covenants, representations or warranties hereunder, (ii) the infringement of the
Intellectual Property rights of a third party arising from Avecia’s manufacture of API
hereunder other than to the extent arising out of Avecia’s use of Customer’s Intellectual
Property in its manufacture of API hereunder, (iii) claims for personal injury or death,
damage to property, for failure to comply with operating permits or Regulatory Requirements
relating to the operation of the Facility during the course of Avecia’s manufacturing and
processing activities or (iv) arising out of gross negligence or willful misconduct on the
part of Avecia or any of its agents or employees; in each case (i) through (iv) above, other
than to the extent caused by (a) any breach of the covenants, representations or warranties of
Customer hereunder or (b) the gross negligence or willful misconduct of Customer hereunder.
	 
	12.2	 	Customer shall indemnify and hold Avecia harmless from all losses, liabilities, damages and
expense (including reasonable attorneys’ fees and costs) incurred as a result of any claim,
demand, action or other proceeding by a third party to the extent caused by (i) any breach by
Customer of the covenants, representations or warranties of Customer hereunder, (ii) the
infringement of the Intellectual Property rights of a third party arising out of Avecia’s use
of Customer’s Intellectual Property in Avecia’s manufacture of API or the provision of other
services for Customer hereunder, (iii) the use or sale of API by Customer, Customer’s
Affiliates and Customer Partners, or by any other third party or (iv) any use of Avecia’s
Intellectual Property in the manufacture of API by Customer, a Customer Partner or any other
third party appointed a sub-licensee of Customer pursuant to rights granted to Customer
pursuant to Section 13; in each case (i) and (ii) other than to the extent caused by (a) a
breach of the covenants, representations or warranties of Avecia hereunder, (b) the gross
negligence or willful misconduct of Avecia hereunder or (c) any API supplied hereunder that
does not conform to API Requirements, provided, however, that, in

11

 

EXECUTION COPY

	 	 	such case, Customer shall have notified Avecia of such non-conformance within the applicable
time period prescribed in Section 10.1.

	12.3	 	NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EXCEPT FOR WILLFUL MISCONDUCT AND
RECKLESS DISREGARD, (A) * FOR ANY AND ALL LOSSES OR DAMAGES RESULTING FROM ANY CAUSE
WHATSOEVER OR WITH RESPECT TO ANY * HEREUNDER, INCLUDING, WITHOUT LIMITATION, ANY LIABILITY
RELATING TO *, * OR* AS SET FORTH IN SECTION 18, SHALL IN NO EVENT EXCEED *, AND (B) IN NO
EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INCIDENTAL PUNITIVE OR CONSEQUENTIAL DAMAGES,
WHETHER THE CLAIM IS IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE.

13. Intellectual Property.

	13.1	 	Nothing in this Agreement shall affect the ownership by either Party of any Intellectual
Property or process owned by or in the possession of that Party as of the Effective Date or
Intellectual Property developed independently of the work undertaken pursuant to this
Agreement by any employee of that Party without reference to any of the Confidential
Information disclosed by the other Party (“Independent Intellectual Property”). Other than
giving Avecia the right to manufacture API for Customer, nothing in this Agreement shall give
either Party the right to use the other Party’s Independent Intellectual Property.
	 
	13.2	 	Intellectual Property generated, developed, discovered or invented in connection with work
conducted pursuant to this Agreement by the Parties relating to the composition of API or
other product-specific invention shall *. Intellectual Property generated, developed,
discovered or invented in connection with work conducted pursuant to this Agreement relating
to Avecia’s process to manufacture API or other process-related invention shall *.
	 
	13.3	 	Avecia hereby grants to Customer a * , * license, with the right to grant sublicenses, to
Avecia’s interest in any Intellectual Property generated, developed, discovered or invented
during work conducted pursuant to this Agreement with general application to manufacturing
processes (including as specifically applicable to the manufacture of API) to the extent that
such Intellectual Property can be used to enhance the manufacture of API.
	 
	13.4	 	During the term of this Agreement, Avecia hereby grants to Customer a *license, with the
right to grant sublicenses, to Avecia’s process to manufacture API with respect to the
manufacture of API (i) in an amount up to * of Customer’s requirements for API during any
Agreement Year commensurate with the minimum volume requirements of Section 6.1 or (ii) for
such greater amount to the extent that Avecia does not supply Customer its requirements for
API in excess of such *during any such Agreement Year for any reason other than a breach of
this Agreement by Customer.
	 
	13.5	 	Avecia hereby grants to Customer a * license, with the right to grant sublicenses, to
Avecia’s process to manufacture API (the “Licensed Process”), such license to take effect *,
subject to payment to Avecia of the following royalties:* for each of the *of

12

 

EXECUTION COPY

	 	 	API or portion thereof manufactured during any license year using the Licensed Process; * for
each * of API or portion thereof so manufactured during such license year in excess of *; with
such royalty being prorated linearly for such * of API or portion thereof so manufactured
during such license year between * and *.

	13.6	 	Each Party shall be the sole owner of all regulatory filings and all governmental approvals
obtained by such Party from any Regulatory Authority with respect to the API.

14. Confidentiality.

	14.1	 	In consideration of the Disclosing Party (Avecia or Customer, as the case may be) disclosing
Confidential Information to the Receiving Party (Avecia or Customer, as the case may be), the
Receiving Party hereby undertakes to maintain as confidential all such Confidential
Information, and it will not use or disclose any of such Confidential Information in whole or
in part save for purposes envisaged in this Agreement.
	 
	14.2	 	The foregoing restrictions on the Receiving Party shall not apply to any Confidential
Information which:

	 	(a)	 	was already in the Receiving Party’s possession and at its free disposal before the
disclosure hereunder to it;
	 
	 	(b)	 	is hereafter disclosed to, purchased or otherwise legally acquired by the Receiving
Party by or from a third party who has not derived it, directly or indirectly, from the
Disclosing Party;
	 
	 	(c)	 	is or becomes available to the public or otherwise in the public domain through no
act or default on the part of the Receiving Party, its agents or employees; or
	 
	 	(d)	 	has been developed by the Receiving Party independently of the Disclosing Party
without reference to any of the Confidential Information disclosed by the Disclosing
Party.

	14.3	 	In order to secure the obligations under this Section 14, the Receiving Party agrees to
exercise reasonable precautions to prevent and restrain the unauthorized disclosure and use of
information subject to confidentiality, including restricting access to such information to
such of its employees and representatives (i) as are bound to keep such information
confidential and (ii) who need to have such access for the purposes of this Agreement.
	 
	14.4	 	The confidentiality obligations under this Section 14 shall not apply to the extent that a
Party is required to disclose information by Applicable Law, regulation or order of a
governmental agency or a court of competent jurisdiction or otherwise required by a
Governmental Authority (including, without limitation, the requirement to announce and file a
copy of this Agreement with the U.S. Securities and Exchange Commission). In connection with
such disclosure, such Party shall provide written notice thereof to the other Party, use
reasonable efforts to consult with the other Party with respect to such disclosure and use
reasonable efforts to provide the other Party sufficient opportunity to object to any such
disclosure, to request confidential

13

 

EXECUTION COPY

	 	 	treatment thereof or to redact any of such information not required to be so disclosed,
provided that each of the foregoing are subject to such Party’s legal obligations and to the
extent practical under the circumstances.

	14.5	 	Any of Customer’s Affiliates and any Customer Partner shall have access to Confidential
Information of Avecia as reasonably necessary in connection with its agreement with Customer
provided that it is bound by confidentiality terms in connection therewith which are no less
onerous than those set forth herein.
	 
	14.6	 	The terms of this Section 14 shall not be construed to limit either Party’s right to
independently make, develop or acquire products, processes or concepts without use of the
other Party’s Confidential Information, even if similar. Neither Party shall have any
obligation to limit or restrict the assignment of its employees or consultants as a result of
their having had access to Confidential Information of the other Party.
	 
	14.7	 	The provisions of this Section 14 shall survive termination or expiry of this Agreement and
shall continue for a period of * from the date of such termination or expiry.
	 
	14.8	 	From time to time during the term of this Agreement, Customer may have employees assigned to
work full-time at the Facility. For clarification purposes, Customer shall treat all
Confidential Information disclosed to or learned by such employees at the Facility as
Confidential Information of Avecia for purposes of this Section 14. Furthermore, Customer
shall require that such Customer employees review and sign an employee acknowledgement of
confidentiality agreement in form and substance reasonably satisfactory to Avecia.

15. Force Majeure.

Neither Party is liable for any failure to perform or delay in performing any obligation under this
Agreement, if such failure or delay is due to fire, flood, strike or any other industrial
disturbance, war, embargo, legal prohibition, terrorism, insurrection, regulatory delay or any
other cause beyond the reasonable control of such defaulting Party preventing or delaying the
performance of such obligations. The Party so affected will, upon giving notice thereof to the
other Party, be excused from such performance to the extent of such prevention, restriction or
delay. Except in the case of strike or similar work stoppage, the affected Party is obligated to
use its commercially reasonable efforts to avoid or remove such causes of non-performance and to
continue performance with the utmost dispatch whenever such causes are removed.

Neither Party shall be entitled to relief under this Section 15 for any delay or failure in
performing any of its payment obligations under this Agreement.

16. Termination; Consequences of Termination.

14

 

EXECUTION COPY

	16.1	 	Without prejudice to any other rights or remedies which may be available to them, the Parties
may terminate this Agreement at any time by mutual agreement of both Parties in writing.
	 
	16.2	 	Without prejudice to any other rights or remedies which may be available to them, either
Party may terminate this Agreement with immediate effect by giving written notice of
termination to the other Party if the other commits a material breach of any of the provisions
of this Agreement and, in the case of a breach capable of being remedied, fails to remedy such
breach within * of receiving notice from the non-breaching Party specifying such and requiring
the same to be remedied, provided, however, if, for any reason other than an event of force
majeure referred to in Section 15 or a failure of Customer to meet its obligations under this
Agreement, Avecia fails to Deliver the API set out in the applicable purchase order within *
following the date of Delivery set out in such purchase order, * may terminate this agreement
for material breach effective upon written notice if * fails to cure such breach *of receiving
notice of such breach *.
	 
	16.3	 	Without prejudice to any other rights or remedies which may be available to Customer,
Customer may terminate this Agreement by giving written notice of termination to Avecia if
Customer, in its sole discretion, determines that the drug product containing API shall not be
further developed or marketed by Customer, Customer’s Affiliates and Customer Partners.
	 
	16.4	 	Subject to Section 16.5 and without prejudice to any other rights or remedies which a Party
may have, upon termination of this Agreement, howsoever the same occurs, each Party shall:

	 	(a)	 	immediately pay to the other all sums which at the date of termination are due and
payable to the other hereunder;
	 
	 	(b)	 	immediately cease all use of any property of the other, including, without
limitation, any Intellectual Property of the other Party, except as permitted under
Section 13; and
	 
	 	(c)	 	at the expense of the requesting Party, promptly return to the other Party any
property of the other in its possession, custody or control.

	16.5	 	If (i) the Parties terminate this Agreement pursuant to Section 16.1, (ii) Avecia terminates
this Agreement in accordance with Section 16.2 or (iii) Customer terminates this Agreement in
accordance with Section 16.3, Customer shall purchase all amounts of API which have been
manufactured but not yet delivered and pay to Avecia Avecia’s costs related to any API which
is in the process of being manufactured or is in the Avecia manufacturing schedule as of the
date of such termination to fulfill Customer’s firm commitment portion of the effective
Rolling Forecast, including, without limitation, Avecia’s cost for any raw materials purchased
in anticipation of meeting the firm commitment portion of the effective Rolling Forecast,
subject to Section 25. Customer shall have the right to take possession of any such raw
materials or unfinished API at it expense.

15

 

EXECUTION COPY

	16.6	 	If it is determined by the final decision of an arbitrator pursuant to Section 26.3 that
Customer has committed a material breach of this Agreement and has not cured such breach
within * after notice thereof, Avecia shall thereafter have the right to * pursuant to *
written notice* (except with respect to the * pursuant to *), it being understood, however,
that, in the event that this Agreement is terminated for any other reason, Avecia shall not
have the right thereafter * pursuant to *.
	 
	16.7	 	Sections 12, 13, 14, 17 to 19, and 21 to 26 shall survive the termination of this Agreement
howsoever the same occurs.

17. Regulatory; Facility Access; Audits.

	17.1	 	Except as otherwise set forth in the proviso to this sentence, Avecia shall be responsible
for obtaining at its own expense all permissions, licenses and approvals necessary to
discharge its obligations under this Agreement; provided, however, that Customer shall pay
for, or reimburse Avecia for, all reasonable work carried out by Avecia in support of
regulatory filings and preparation for any PAI, including, without limitation, Avecia staff
participation in the PAI or practice PAIs. If, however, Avecia fails a PAI due to its gross
negligence or willful misconduct, or a failure in the Avecia general Quality systems not
related specifically to API, then Customer will not be required to pay for the PAI or
reimburse Avecia. Once the cumulative total of API produced under this Agreement reaches *,
Customer will no longer be charged for additional PAIs.
	 
	17.2	 	If Customer requests that Avecia adopt any approach to cGMP or Avecia operating standards
which is different from Avecia’s operating norms, the change will only be implemented if
Avecia agrees to the change, and Avecia will charge Customer for Avecia’s cost to deliver the
request, except when Customer makes such a request because Avecia is operating outside
industry norms (as reasonably demonstrated by Customer), Regulatory Requirements, cGMP
requirements or contractual commitments.
	 
	17.3	 	Avecia shall promptly furnish Customer with such information and documentation as Customer
may request relating to any regulatory filings or submissions for API. Avecia shall provide
Customer with a copy of all proposed submissions to any regulatory agency associated with the
manufacture of API hereunder for Customer’s review and approval.
	 
	17.4	 	Avecia shall permit Customer’s employees, consultants and/or representatives to have
reasonable access to the Facility for the purpose of verifying quantities of Customer
supplied materials and API and observing manufacturing and related activities, including
access to certain agreed documents (“Reasonable Access”); provided that such persons agree to
be bound by a mutually acceptable confidentiality agreement.

16

 

EXECUTION COPY

	17.5	 	Customer shall have the right to conduct, upon reasonable notice and at its own expense,
periodic technical, quality, and environmental health and safety audits. Avecia shall give
Reasonable Access to Customer for purposes of auditing the Facility. Preferably * notice
should be reasonable, but Avecia will provide Customer immediate access in case of rejections
or emergency conditions.
	 
	17.6	 	Avecia, if it is so aware (or as soon as it becomes aware) will promptly advise Customer if
any regulatory agency intends to inspect the Facility and the nature of the inspection.
Customer shall have the right to observe such inspection relating to the manufacture of API.
Avecia shall promptly provide a report of the results of such inspection to Customer. In
addition, Avecia shall promptly notify Customer of any notice of deficiencies by any
regulatory agency, and provide Customer with a copy of the unredacted copies of any FDA 483(s)
and Establishment Inspection Reports or their equivalents issued as a result of said
inspection and any follow-up written communications between Avecia and the relevant Government
Authority if, and only if, such reports or FDA 483(s) do not contain third party confidential
information. Avecia will use best efforts to correct all identified deficiencies in a timely
manner and advise Customer periodically of progress being made, as well as when all
deficiencies are corrected.
	 
	17.7	 	Avecia will complete the Requalification Plan* within *of receipt of a purchase order if the
scope of the Requalification Plan remains unaltered from the current scope (i.e. as
*).
	 
	17.8	 	The Parties shall cooperate to obtain approval for Avecia to become responsible for all API
release testing. As part of such cooperation, it is intended that quality control methods
will be validated at the Facility and Avecia’s quality control laboratory will be included in
the next Regulatory Authority Approval.
	 
	17.9	 	Customer Partners shall have the same rights as Customer under this Section 17, subject to
reasonable confidential obligations.
	 
	17.10	 	Avecia shall not have the right to subcontract, sublicense or otherwise delegate all
or any portion of its obligations under this Agreement without Customer’s prior written
approval. For the avoidance of doubt, Customer has already granted such approval for the
subcontractors approved as part of the process validation and subsequent production conducted
in 2004.

18. Recalls.

	18.1	 	Each Party shall keep the other Party fully informed of any notification, or other
information of which it has actual knowledge, which might result in the Recall, Seizure or
other enforcement action relating to the API.
	 
	18.2	 	If Avecia independently believes that a withdrawal of API or Recall of drug product
containing API or field corrective action may be necessary or appropriate, Avecia

17

 

EXECUTION COPY

	 	 	shall so notify Customer of Avecia’s conclusion within * and the Parties shall cooperate with
each other to ascertain the necessity and nature of such action.

	18.3	 	Promptly after Customer notifies a Regulatory Authority of a withdrawal of API or Recall of
drug product containing API, Customer shall so notify Avecia as soon as possible and, to the
extent related to Avecia’s supply of API pursuant to this Agreement, no later than within
twenty-four hours. If requested by Customer, Avecia shall reasonably assist Customer, and, if
applicable the Customer Partner(s), in the investigation to determine the cause and extent of
the problem. In such case, *shall * with respect thereto.
	 
	18.4	 	Notwithstanding anything to the contrary in the foregoing, Customer shall make the final
decision as to whether API or drug product containing API is withdrawn or Recalled.
	 
	18.5	 	If any Governmental Authority withdraws its approval to sell the API or drug product
containing API or issues a directive or request that all or specified quantities of the API or
drug product containing API be Recalled for product safety reasons or Customer reasonably
determines that all or specified quantities of the API or drug product containing API should
be withdrawn or Recalled, * shall * with the *to the extent *.
	 
	18.6	 	For purposes of this Section 18, “Recall” shall mean any action by Customer or Customer
Partner to recover title to or possession of drug products containing API sold or shipped to
third parties. For purposes of this Section 18, “Seizure” shall mean any action by any
Governmental Authority to detain or destroy API. For the purposes of this Section 18,
(a) neither “Recall” nor “Seizure” shall mean any actions taken by Customer or Customer
Partner that are solely related to nonpayment or contract issues and are not related to any
toxicity, safety, efficacy or Regulatory Requirements-related issues; and (b) references to
“API” include drug product containing API.

19. Announcements and Publicity.

Except in connection with disclosures under Section 14.4, the Parties agree that they shall not
make any official press release, announcement or other formal publicity relating to the
transactions which are the subject of this Agreement, or any ancillary matter, without first
obtaining in each case the prior written consent of the other Party, which consent shall not be
unreasonably withheld.

20. Assignment and Change of Control.

This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their
respective legal successors but shall not otherwise be assignable by either Party without the prior
written consent of the other Party; provided, however, that (i) either

18

 

EXECUTION COPY

Party, without the need for consent, shall assign this Agreement and its rights and delegate its
obligations hereunder in connection with the transfer or sale of all or substantially all of its
business and assets to which this Agreement relates, or in the event of its merger, consolidation,
change in control or similar transaction; and (ii) Customer, without the consent of Avecia, may
assign this Agreement, in whole or in part, to a Customer Partner or Customer Affiliate; *, in the
event of * to this *, unless * has a * at the time of *, subject to all of * and * . Any permitted
assignee shall assume all obligations of its assignor (and in the case of assignment by Genta, be
deemed a “Customer” hereunder) and otherwise be subject to all of the terms and conditions under
this Agreement (and, to the extent applicable due to their ongoing activities, Genta and its
Affiliates would each be deemed a “Customer Partner” of Genta’s assignee). Any purported
assignment in violation of this Section 20 shall be void. All Customer Partners or Customer’s
Affiliates purchasing API as provided herein shall be subject to all obligations, terms and
conditions under this Agreement to the same extent as Customer.

21. Integration and Variation.

This Agreement shall constitute the sole and exclusive agreement between the parties regarding the
subject matter hereof. Any other agreement or arrangement between the Parties relating to the sale
of API by Avecia to Customer, including the Manufacturing and Supply Agreement dated December 20,
2002, as subsequently amended by the Parties, and any letter or side agreements relating thereto
(the “December 20, 2002 Agreement”), is hereby superceded and terminated as of the Effective Date,
and the provisions of this Agreement shall govern the rights, remedies and obligations of the
Parties with respect to any sale of API by Avecia to Customer, provided that the terms of the
letter agreements attached as Appendix 6 shall remain in full force and effect and are incorporated
herein as part of this Agreement. No variation or amendment of this Agreement shall bind a Party
unless made in writing in the English language and agreed to in writing by duly authorized officers
of both Parties.

22. Illegality.

If any provision of this Agreement is agreed by the Parties to be illegal, void or unenforceable
under any Applicable Law or if any court of competent jurisdiction in a final decision so
determines, this Agreement shall continue in full force save that such provision shall be deemed to
be excised herefrom with effect from the date of such agreement or decision or such earlier date as
the Parties may agree.

23. Waiver.

A failure by either Party to exercise or enforce any rights conferred upon it by this Agreement
shall not be deemed to be a waiver of any such rights or operate so as to bar the exercise or
enforcement thereof at any subsequent time or times.

19

 

EXECUTION COPY

24. Notices.

All notices and any other communications given or made in relation to this Agreement shall be in
writing and delivered by hand, registered mail or recognized overnight mail service to the address
of the Party set forth below:

If to Avecia:

Avecia Biotechnology Inc.

125 Fortune Boulevard

Milford, MA.

01757

Attention: President

If to Customer:

Genta Incorporated

200 Connell Drive

Berkeley Heights, NJ

07922

Attention: Vice President, Manufacturing Operations

cc: Senior Director, Legal Affairs

25. Duty to Mitigate.

Each of the Parties shall use all reasonable efforts to mitigate any costs, losses or expenses due
to be incurred or suffered by the other Party in connection with the performance or non-performance
of this Agreement.

26. Law and Jurisdiction.

	26.1	 	This Agreement is governed by and shall be construed and interpreted in accordance with the
laws of the State of Delaware.
	 
	26.2	 	The Parties shall use reasonable efforts, acting in good faith, to reach consensus on all
matters as expeditiously as possible. Should the Parties be unable to reach consensus on an
issue, such issue shall be elevated to the respective presidents of each Party for resolution.
	 
	26.3	 	Any dispute not disposed of in accordance with Section 26.2 shall be disposed of by binding
arbitration under the rules of the American Arbitration Association. The arbitration shall
take place in New York City, NY. The arbitrator shall be bound to follow the applicable
provisions of this Agreement and Delaware law in adjudicating any dispute. It is agreed by the
Parties that the arbitrator’s decision is final, and that neither Party may take action,
judicial or administrative, to overturn the decision. The

20

 

EXECUTION COPY

	 	 	judgment rendered by the arbitrator may be entered in any court having jurisdiction thereof.

21

 

EXECUTION COPY

IN WITNESS WHEREOF, this Agreement has been entered into the day and year first above written.

	 	 	 	 	 
	AVECIA BIOTECHNOLOGY INC	 	 
	 
	 	 	 	 
	BY:
	 	 	 	 
	 

	 	 

NAME:
	 	 
	 

	 	TITLE:	 	 

 

 

EXECUTION COPY

IN WITNESS WHEREOF, this Agreement has been entered into the day and year first above written.

	 	 	 	 	 
	GENTA INCORPORATED	 	 
	 
	 	 	 	 
	BY:
	 	 	 	 
	 

	 	 

NAME:
	 	 
	 

	 	TITLE:	 	 

 

 

Appendix 1 *

Appendix 1

 

Appendix 2 *

API PRICE

Appendix 2

 

Appendix 3

NEW PROCESS STRATEGY

The process change strategy to move Customer from the Current Process to the New Process contains
*:

*

This approach has been used by Avecia and their clients to support site technical transfers and
major process change in late Phase clinical products, and it has been successfully reviewed by the
regulators. At this stage the strategy is a good basis for planning to implement the new process.
It is planned that Customer with Avecia support will seek specific regulatory advice/approval on
the process change strategy.

Appendix 3

 

Appendix 4 *

Appendix 4

 

Appendix 5

QUALITY AGREEMENT

	1.	 	OVERVIEW

	 	1.1	 	This Quality Agreement (the “Quality Agreement”) serves to define the
responsibilities of Genta and Avecia with regard to manufacturing, packaging,
inventory management and/or testing of [drug substance] (the “API”). In addition, this
Quality Agreement specifies a process to ensure the API complies with all applicable
Specifications and other requirements and that the API will be released in accordance
with the manufacturing process agreed to by both Parties (the “Manufacturing
Process”).
	 
	 	1.2	 	It is the responsibility of Genta and Avecia to ensure that this Quality
Agreement complies with Applicable Laws. Genta and Avecia will ensure that the
respective Standard Operating Procedures (SOPs) utilized in the course of the Services
comply with Applicable Laws. Any changes to this Quality Agreement must be contained
in a written amendment signed by both parties.
	 
	 	1.3	 	Genta and Avecia will carry out this Quality Agreement in accordance with the
Genta or Avecia identified and approved SOPs. In the event of a conflict between this
Quality Agreement and the applicable SOP, the parties will confer and agree on a
mutually acceptable solution.
	 
	 	1.4	 	This Quality Agreement is intended to comply with the requirements for
quality agreements contained in Applicable Laws including, but not limited to, the
applicable portions of the U.S. Code of Federal Regulations and applicable FDA
guidance documents as well as ICH guidelines, USP, EP, and EMEA requirements
(“Regulatory Requirements”).

	2.	 	DEFINITIONS

	 	2.1	 	All capitalized terms used but not otherwise defined in this Quality
Agreement shall have the same meaning given to such terms in the Supply Agreement.

Appendix 5

 

	3.	 	SPECIFICATIONS

	 	3.1	 	Genta is responsible for providing a controlled copy of the approved API
Specifications for the API to Avecia. Genta is responsible for notifying Avecia of any
revisions to approved API Specifications and providing controlled copies. Avecia is
responsible for generating and maintaining any internal specifications as they relate
to the Manufacturing Process.

	4.	 	FACILITIES, MANUFACTURING

	 	4.1	 	Avecia is responsible for maintaining all licenses, registrations and other
authorizations as are required to operate the Facility according to cGMP and
Applicable Laws.
	 
	 	4.2	 	Avecia is responsible for maintaining and operating the Facility in
accordance with cGMP and other Applicable Law. This includes, but is not limited to,
conducting all activities associated with preventative maintenance, equipment and
instrument calibration, and validation where applicable. Avecia is responsible for
ensuring that qualified, trained individuals are assigned to the manufacturing and
testing of each batch of the API.
	 
	 	4.3	 	Avecia is responsible for manufacturing each batch of the API in accordance
with the requirements of this Quality Agreement.

	5.	 	RAW MATERIALS/COMPONENTS/LABELING

	 	5.1	 	Avecia will qualify the raw material suppliers to ensure compliance with cGMP
and other Applicable Laws prior to use of raw materials or components in a Genta
campaign. Raw materials and components will be stored per Avecia specifications in
accordance with cGMP, other Applicable Laws, and Genta’s regulatory filings. The
suppliers utilized for the currently validated process should remain consistent with
Genta’s regulatory filings.
	 
	 	5.2	 	Packaging and labeling specifications will be prepared by Avecia and
forwarded to Genta’s Quality Assurance group (“Genta QA”) for approval prior to use in
the Manufacturing Process.
	 
	 	5.3	 	Avecia is responsible for the verification and documentation of animal or
human source raw materials and components associated with the manufacture of the API.
Avecia is responsible for notifying Genta in

Genta Incorporated

200 Connell Drive      §  Berkeley Heights      § New Jersey 07922      § Phone: 908.286.9800

 

 

	 	 	 	writing of any raw materials, which are derived from animal or human sources.

	6.	 	SAMPLING AND TESTING

	 	6.1	 	Avecia will generate and provide to Genta all batch documentation as required
under the Supply Agreement including, but not limited to, an approved Certificate of
Analysis (CofA) and copies of all relevant data used to generate the CofA. The CofA
will list the results from all analytical testing required per the approved API
Specification. Avecia will forward the approved CofA and associated documentation to
Genta with the QA reviewed copy of the executed batch record.
	 
	 	6.2	 	Avecia is responsible for any method transfers and the reporting of results
of these method transfers. Avecia will forward a copy of the method transfer report
and associated results to Genta for review and approval.

	7.	 	BATCH NUMBERING

	 	7.1	 	Avecia is responsible for assigning a unique lot/batch number to each batch
per Avecia’s internal SOP.

	8.	 	DEVIATIONS, OUT-OF-SPECIFICATIONS (OOS)

	 	8.1	 	Avecia is responsible for investigating, resolving and documenting all
deviations and investigations from the master batch record, SOP’s and Specifications.
Any deviations, which have the potential to impact API quality, will be documented per
Avecia quality systems and reported to Genta QA. These deviations include, but are not
limited to, issues arising from raw material handling, — manufacturing operations, API
storage, sampling, labeling, packaging or distribution. In addition, any associated
CAPA (Corrective Actions Preventive Actions) will also be provided to Genta QA.
	 
	 	8.2	 	Any Out-of-Specification (OOS) resulting from a failure to meet an in-process
or release criteria as defined in an approved specifications will be documented per
Avecia quality systems and must be reported to Genta QA.

	9.	 	CHANGE CONTROL

	 	9.1	 	Any changes to the Facilities, equipment or Manufacturing Process utilized to
manufacture the API for Genta which have the potential to

Genta Incorporated

200 Connell Drive      §  Berkeley Heights      § New Jersey 07922      § Phone: 908.286.9800

 

 

	 	 	 	impact API quality or any licenses required to operate the Facility, must be
reported to Genta QA by Avecia.

	 	9.2	 	Genta shall provide a turn around time of * on all Avecia documents requiring
Genta review, otherwise, agreement shall be implied and the documents made effective.

	10.	 	BATCH RECORDS

	 	10.1	 	Avecia will generate, complete and maintain all relevant batch records
related to the manufacture of the API. All master batch records must be approved by
Genta QA prior to use in cGMP manufacturing. Any change to a previously approved batch
record must be approved, in writing, by Genta QA prior to use. Genta agrees to review
applicable batch records within * of receipt and provide comments for Avecia
correction or approval as applicable.
	 
	 	10.2	 	Copies of executed batch records and associated documentation will be
forwarded to Genta for review prior to further processing and/or use of the API. All
batch records must be reviewed and released by Avecia QA personnel prior to forwarding
to Genta QA. The parties may review batch records at the same time if previously
agreed to by both parties.
	 
	 	10.3	 	Avecia will maintain batch records and related documents as required under
Avecia SOPs and cGMP. Express written approval from Genta is required prior to the
destruction of any batch records and related documents.

	11.	 	API RELEASE

	 	11.1	 	Subject to the Supply Agreement, Genta QA will be responsible for final
release of the API for further processing and/or use in addition to any Qualified
Person (QP) release as required. Genta will provide a release authorization document
to Avecia upon resolution of any items that arise during Genta QA review.

	12.	 	STORAGE, PACKAGING AND DISTRIBUTION

	 	12.1	 	Avecia will store the API at the Facility in accordance with the API
Specifications and the Supply Agreement until shipment/distribution is approved by
Genta QA. Genta QA will provide written authorization for shipment as applicable.

Genta Incorporated

200 Connell Drive      §  Berkeley Heights      § New Jersey 07922      § Phone: 908.286.9800

 

 

	 	12.2	 	Avecia will maintain an accurate release status and inventory of the API.
	 
	 	12.3	 	Avecia will package shipments of the API in containers and ship in conditions
previously approved by both parties.

	13.	 	AUDITS, INSPECTIONS

	 	13.1	 	Genta will be entitled to conduct one quality systems audit of Avecia *, as
well as “for cause” audits resulting from facility changes, potential API quality
issues or patient safety issue. In addition, Genta may monitor batch API activities as
they relate to Genta APIs.
	 
	 	13.2	 	When quality systems audits are performed, Genta will issue a report * of the
audit completion. Avecia will respond to the audit findings * of receipt of the audit
report. Genta will be entitled to perform a follow-up assessment to ensure that
critical/major items are corrected.
	 
	 	13.3	 	Each party agrees to notify the other of any communication with a Regulatory
Authority or any planned or unplanned inspections related to manufacture or
distribution of the API.
	 
	 	13.4	 	Each party agrees to provide copies of all pertinent documentation necessary
for the other party to respond to inquiries and audits by Regulatory Authorities.
	 
	 	13.5	 	Genta may conduct QA reviews of documents (i.e. executed batch records,
method transfer reports, etc.), as needed, at Genta or at Avecia.

	14.	 	COMPLAINTS, API WITHDRAWAL/PRODUCT RECALL, FIELD ALERTS

	 	14.1	 	Avecia agrees to assist Genta in the investigation of any field alerts, API
Recalls/withdrawal or API complaints. Genta agrees to notify Avecia of any relevant
field alerts, API complaints or API Recalls/withdrawals.

	15.	 	THIRD PARTIES

	 	15.1	 	Any third parties utilized by Avecia to perform analytical testing or other
activities must be made known to and approved by Genta and must have been audited and
approved by Avecia prior to initiation of activities by those third parties.

APPROVALS:

Genta Incorporated

200 Connell Drive      §  Berkeley Heights      § New Jersey 07922      § Phone: 908.286.9800

 

 

	 	 	 	 	 
	 

	 	 	 	 
 
	Bonnie Pappacena

	 	 	 	J.P Rodrique
	Senior Director

	 	 	 	Director
	Quality Assurance

	 	 	 	Quality Assurance
	Genta Incorporated

	 	 	 	Avecia Biotechnology, Inc.
	 
	 	 	 	 
	ACKNOWLEDGEMENTS:
	 
	 	 	 	 
	 

	 	 	 	 
 
	Bharat Mehta

	 	 	 	Kelly Behrendt
	Vice President

	 	 	 	Vice President
	Manufacturing Operations

	 	 	 	Operations
	Genta Incorporated

	 	 	 	Avecia Biotechnology, Inc.

Genta Incorporated

200 Connell Drive      §  Berkeley Heights      § New Jersey 07922      § Phone: 908.286.9800

 

 

Appendix 6 Letter Agreements *

Appendix 6EX-10.2

Exhibit 10.2

AMENDMENT NO. 3 TO

LEASE AND PARTIAL TERMINATION AGREEMENT

     This Amendment No. 3 to Lease and Partial Termination Agreement (this “Amendment No. 3 to
Lease”), dated as of May 27, 2008, is made between THE CONNELL COMPANY, a New Jersey corporation
(“Landlord”), and GENTA INCORPORATED, a Delaware corporation (“Tenant”).

     WHEREAS, Landlord and Tenant entered into the Lease dated as of June 28, 2000, which was
amended by Amendment No. 1 to Lease dated as of June 19, 2002, Amendment No. 2 to Lease dated as
of February 25, 2003 and the letter agreement dated April 15, 2008 (as amended, the “Lease”;
capitalized terms used herein and not otherwise defined having the meaning assigned thereto in the
Lease) pursuant to which Tenant is leasing the Demised Premises in the Building from Landlord;

     WHEREAS, Landlord and Tenant desire to terminate the lease of a portion of the Demised
Premises (consisting of 69,201 rentable square feet located on the fifth floor of the Building),
prior to its scheduled expiration date;

     WHEREAS, in connection with the early termination of the lease of such fifth floor space,
Tenant will pay Landlord certain amounts as a termination fee; and

     WHEREAS, Landlord and Tenant desire to reflect such termination and amend certain portions of
the Lease to, among other things, reflect the same;

     NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

     SECTION 1. Termination.

     On May 31, 2008 (the “Fifth Floor Termination Date”) the Lease shall automatically terminate
with respect to the Fifth Floor Terminated Space (as defined below) only, with such termination
having the same force and effect as if the Fifth Floor Termination Date were the originally
scheduled expiration date of the Lease with respect to the Fifth Floor Terminated Space; provided,
however it is understood and agreed that the Fifth Floor Terminated Space shall be deemed
surrendered and vacated by Tenant in its “as-is” condition (but in broom clean condition and with
all furniture and personal property removed; it being agreed that Tenant shall only be required to
remove the furniture from the Fifth Floor Terminated Space on the earlier of (i) August 31, 2008 or
(ii) fifteen (15) days following Tenant’s receipt of notice from Landlord to have the furniture
removed) rather than in any other condition required in the Lease on the expiration or earlier
termination thereof. Upon Tenant’s compliance with the requirement set forth above to surrender and
vacate the Fifth Floor Terminated Space in broom clean condition and with all furniture and
personal property removed, the parties agree that Tenant’s obligations under the Lease regarding
the surrender of the Fifth Floor Terminated Space shall be deemed satisfied; it being understood
that the foregoing shall not in any way affect any of Tenant’s indemnification obligations under
the Lease. For purposes of clarification, it is understood and agreed that the termination
described herein on the Fifth Floor Termination Date shall not in any way apply to or affect any
portion of the Demised Premises other than the Fifth Floor Terminated Space, and the Lease shall
continue on and after the Fifth Floor Termination Date in full force and effect with respect to all
portions of the Demised Premises other than the Fifth Floor Terminated Space. For purposes of this
Amendment No. 3 to Lease, the “Fifth Floor Terminated

 

 

Space” shall mean the 69,201 rentable square feet of floor area located on the fifth floor of the
Building which is designated as the “Fifth Floor Terminated Space” on Schedule I attached hereto.

     SECTION 2. Amendments to Lease.

     2.1. On the Fifth Floor Termination Date the Lease shall automatically be amended as set
forth in the remaining portions of Section 2 hereof.

     2.2. Section 1.02 of the Lease is amended by inserting the following immediately prior
to the second to last sentence of such Section 1.02 (such second to last sentence begins with
the words “The Demised Premises includes any alterations”):

Notwithstanding any of the foregoing provisions of this Section 1.02, effective
as of the Fifth Floor Termination Date and for all periods of the Term
thereafter, the Demised Premises shall mean (x) the Initial Demised Premises
plus (y) the Additional Expanets Demised Premises (the total rentable
square footage of the Demised Premises being equal to 24,464 rentable square
feet). For purposes of clarification, effective as of the Fifth Floor
Termination Date, the Demised Premises shall not include the Fifth Floor
Terminated Space.

     2.3. Section 1,03 of the Lease is amended by inserting the following at the end of such
Section 1.03:

Notwithstanding any of the foregoing provisions of this Section 1.03, for the
period from (and including) June 1, 2008 up to (and including) February 28,
2010, “Base Rent” shall equal $56,063.33 per month, which equals the sum of the
following amounts:

	 	(a)	 	Initial Demised Premises: $27.50 per rentable square foot of the Initial
Demised Premises per annum, or $352,192.50 in the aggregate per annum
(or $29,349.38 per month), plus
	 
	 	(b)	 	Additional Expanets Demised Premises: $27.50 per rentable
square foot of the Additional Expanets Demised Premises per annum, or
$320,567.50 in the aggregate per annum (or $26,713.96 per month).

In all cases Base Rent during any renewal term shall be governed by Section 4.01 hereof.

     2.4. Section 1.04 of the Lease is amended by deleting such Section 1.04 in its entirety, and inserting in its place the following:

Section 1.04, Termination Payment for Fifth Floor Terminated
Space. As part of the consideration for Landlord’s agreement to allow for
the termination of the Fifth Floor Terminated Space on the Fifth Floor
Termination Date, Tenant shall pay Landlord the following amounts:

	 	(a)	 	On or before May 31, 2008, Tenant shall pay Landlord an amount equal to $1,351,704.04, as follows:

	 	(i)	 	Tenant shall pay Landlord $240,131.25 on or before May 31, 2008.
	 
	 	(ii)	 	Landlord and Tenant acknowledge that as of the date
of Amendment No. 3 to Lease, the Security Deposit being held by
Landlord equals $1,111,572.79, and Landlord shall, on or before May
31, 2008, use

2

 

	 	 	 	and apply the full amount of such Security Deposit to satisfy the balance
of the amount Tenant owes Landlord under this clause (a).

	 	(b)	 	Tenant shall pay Landlord an amount equal to $1,978,593.98
upon the earlier to occur of (x) Tenant’s receipt of at least $5,000,000
from a business development deal or (y) July 1, 2009. In the event Tenant
achieves the trigger set forth in clause (x) above, Tenant shall promptly
notify Landlord in writing thereof.

Ail amounts referred to above shall be paid to Landlord by wire transfer in
immediately available funds in U.S. Dollars, to the following account: Wachovia
Bank, National Association, 190 River Road, Summit, NJ 07901, Attn: Ms. Kathy
Murphy, Senior Vice President; ABA: 031201467; S.W.I.F.T.: PNBPUS 33; For
Credit to the A/C of: The Connell Company; Account Number: 2000010817252, or to
such other account as Landlord may specify in writing to Tenant.

     2.5. Section 1.05 of the Lease is amended by inserting the following at the end of such
Section 1.05:

For purposes of clarification, it is understood that, with respect to the Fifth
Floor Terminated Space only, the Term of this Lease shall expire on the Fifth
Floor Termination Date.

     2.6. Section 1.06 of the Lease is amended by inserting the following words immediately
prior to the last sentence of such Section 1.06 {such last sentence begins with the words “The
determinations of Tenant’s”):

Notwithstanding any of the foregoing provisions of this Section 1.06, effective
as of the Fifth Floor Termination Date and for all periods of the Term
thereafter, Tenant’s Pro Rata Share shall be 7.837%, calculated as follows:
Demised Premises of 24,464 rentable sq. ft. divided by the rental Area of
Building of 312,143 sq. ft, = 0.07837 x 100 = 7.837%.

     2.7. Sections 1.08 and 1.09 of the Lease are amended by deleting such Sections 1.08 and 1.09 in their entirety, and inserting in their place the following:

Section 1.08. Security Deposit and Letter of Credit. The parties
acknowledge that prior to June 1, 2008 Tenant was required to have on deposit
with Landlord a Security Deposit and have a Letter of Credit issued in favor of
Landlord. Landlord and Tenant agree that from and after June 1, 2008, Tenant
shall not be required to have on deposit with Landlord any Security Deposit or
have any Letter of Credit issued in favor of Landlord. Landlord agrees to cancel
the Letter of Credit (issued by Bank of America in favor of Landlord in the
amount of $240,131.25) which is in Landlord’s possession as of the date of
Amendment No. 3 to Lease, and Landlord shall execute such documents as is
reasonably requested by Tenant to allow for such cancellation; provided,
however, in no event shall such Letter of Credit be cancelled until Landlord
receives the amounts set forth in clause (a) of Section 1.04 of this Lease (as
such Section 1.04 of the Lease was amended by Section 2.4 of Amendment No. 3 to
Lease). Tenant acknowledges that the Security Deposit being held by Landlord as
of the date of Amendment No. 3 to Lease is being used and applied by Landlord as
set forth in clause (a) of Section 1.04 of this Lease (as such Section 1.04 of
the Lease was amended by

3

 

Section 2.4 of Amendment No. 3 to Lease), and that upon execution of Amendment
No. 3 to Lease Tenant has no right or interest of any kind to such amounts or
any other portions of the Security Deposit that were previously used and
applied by Landlord to satisfy obligations of Tenant under the Lease.

     2.8. Section 2.01(n) of the Lease is amended by deleting such Section 2.01(n) in its
entirety, and inserting in its place the words “Intentionally omitted”.

     2.9. Section 2.01(kk) of the Lease is amended by deleting such Section 2.01(kk) in its
entirety, and inserting in its place the words “Intentionally omitted”.

     2.10. Section 2.01(11) of the Lease is amended by deleting such Section 2.01(11) in its
entirety, and inserting in its place the words “Intentionally omitted”.

     2.11. Section 2.01 of the Lease is amended by inserting the following new definitions at the end of such Section:

     (mm) “Amendment No. 3 to Lease” means Amendment No. 3 to Lease and Partial
Termination Agreement dated as of May 27, 2008 between Landlord and Tenant.

     (nn) “Fifth Floor Termination Date” shall mean May 31, 2008

     (oo) “Fifth Floor Terminated Space ” shall have the meaning set forth in
Section 1 of Amendment No. 3 to Lease.

     (pp) “Letter of Credit” shall have the meaning set forth in the Lease as
in effect immediately prior to the effectiveness of Amendment No. 3 to Lease.

     (qq) “Security Deposit” shall have the meaning set forth in the Lease as
in effect immediately prior to the effectiveness of Amendment No. 3 to Lease.

     2.12. Section 4.02 of the Lease is amended by deleting such Section 4.02 in its entirety,
and inserting in its place the words “Intentionally omitted”.

     2.13. Section 4,03 of the Lease is amended by deleting such Section 4.03 in its entirety, and inserting in its place the words “Intentionally omitted”.

     2.14. Section 5.03(g) of the Lease is amended by inserting the words “(and Landlord’s
obligations to refund Tenant, to the extent set forth in Section 5,03(a) hereof, for Operating
Increase Amounts overpaid by Tenant)” after the words “Building Operating Costs” in the first
line of such Section 5.03(g).

     2.15. Section 6.02(c) of the Lease is amended by deleting such Section 6.02(c) in its entirety, and inserting in its place the following:

     (c) Tenant shall not have the right to install or maintain any signs in or
at the Real Estate or visible from the outside of the Demised Premises,

     2.16. Section 8.01(c) of the Lease is amended by inserting the following at the end of such Section 8.01 (c):

4

 

Notwithstanding any of the foregoing provisions of this Section 8.0l(c),
effective as of the Fifth Floor Termination Date and for all periods of the
Term thereafter, access to the parking in the Parking Area shall be granted 4
cars per each 1,000 rentable square feet (i.e. 98 cars for 24,464 rentable
square feet) and of that amount, Landlord will designate up to 10 spaces as
“reserved” for Tenant.

     2.17. Section 8.02(e) of the Lease is amended by inserting the following at the end of such Section 8.02(e):

For purposes of clarification, Landlord and Tenant acknowledge that all of
the Demised Premises have been submetered to measure the electricity actually
consumed in the Demised Premises.

     2.18. Section 9.01 of the Lease is amended by deleting the words “and pharmaceutical research and development use” contained in the first sentence of such Section 9.01.

     2.19. Section 10.01(e) of the Lease is amended by deleting the words “or the expansion options” contained in such Section 10.01(e).

     2.20. Section 14.08 of the Lease is amended by (i) deleting the last sentence of such
Section 14.08 (such last sentence begins with the words “In the event Tenant requests Landlord
to agree to amend Exhibit J”) and (ii) deleting the following words contained in the first sentence
of such Section 14.08:

in the Demised Premises (i) of the materials and animals set forth in Exhibit
J attached hereto in accordance with the approximate levels of usage per year
set forth in such Exhibit J, which materials and animals are used by Tenant
with due care and in compliance with applicable law, in the reasonable and
prudent conduct of Tenant’s business, and only in such areas, if any, of the
Demised Premises as is permitted under applicable law (it being agreed that
Landlord does not, and shall not, make any representation or warranty as to
which areas, if any, of the Demises Premises for which it is permissible
under applicable law to use the materials and animals set forth in Exhibit J
(in the approximate levels of usage set forth in such Exhibit J or
otherwise)) or (ii).

     2.21. Section 16.01 of the Lease is amended by deleting clauses (f) and (g) of such
Section 16.01 (such clauses (f) and (g) dealt specifically with the Letter of Credit and Security
Deposit), and inserting in their place the following:

     (f) the failure of Tenant to pay Landlord any of the amounts set forth
in Section 1.04 of this Lease in accordance with the provision of such
Section 1.04, or any other breach by Tenant of the provisions of Section 1.04
of this Lease.

     2.22. Section 16.07 of the Lease is amended by deleting the last sentence of such Section 16.07.

     2.23. Section 21.01(e) of the Lease is amended by deleting the words “Except as expressly permitted
under Section 14.08(a) hereof” and “except as expressly permitted under Section 14.08(a) hereof” contained in such Section 21.01(e).

5

 

     2.24. Section 2 of Exhibit C-2 to the Lease is amended by inserting the following at the end of such Section 2 of Exhibit C-2:

Landlord and Tenant acknowledge that Landlord has paid Tenant certain
amounts with respect to the Expansion Demised Premises Work Allowance
prior to the date of Amendment Number 3 to Lease, and by such payments
Landlord has satisfied in full all of its obligations under this Lease to
pay the Expansion Demised Premises Work Allowance (and Tenant shall not
have any rights to receive any amounts with respect to the Expansion
Demised Premises Work Allowance (other than those payments it has already
received prior to the date of Amendment Number 3 to Lease)).

     2.25. The Lease is amended by deleting Exhibit J to the Lease in its entirety.

     SECTION 3. MISCELLANEOUS.

     3.1. The parties agree that the entering into this Amendment No. 3 to Lease shall not
constitute an Event of Default under the Lease, and further agree that no Event of Default under
the Lease shall be deemed to have existed as a result of Tenant’s failure to pay any amounts due
under the Lease as of the date of Amendment No. 3 to Lease but not paid as of such date; it being
understood that nothing herein shall constitute a waiver by Landlord of any Event of Default
which may arise after the date of this Amendment No. 3 to Lease as a result of Tenant’s failure to
pay any amounts when due after the date of Amendment No. 3 to Lease.

     3.2. This Amendment No. 3 to Lease shall be governed by and construed in accordance
with the laws of the State of New Jersey (without regard to the conflict of rules thereof).
Any and all notices, requests, certificates and other documents executed and delivered concurrently
with or after the delivery of this Amendment No. 3 to Lease may refer to the Lease without
making specific reference to this Amendment No. 3 to Lease, but nevertheless all such references
shall be deemed to include this Amendment No. 3 to Lease unless the context shall otherwise
require. The Lease shall remain in full force and effect in accordance with its terms as modified
and amended by this Amendment No. 3 to Lease, and is in all respects ratified, confirmed and approved by the parties hereto,

     IN WITNESS WHEREOF, the parties have caused this Amendment No. 3 to be duly executed as
of the day and year first above written.

	 	 	 	 	 	 	 
	THE CONNELL COMPANY	 	WITNESS:
	 
	 	 	 	 	 	 
	By:
	 	/s/ Shane Connell	 	 	 	/s/  Richard E Bartok, Esq.
	 
	 	 	 	 	 	 
	Name:
	 	Shane Connell	 	 	 	 
	Title:
	 	Executive Vice President	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	GENTA INCORPORATED	 	WITNESS:
	 
	 	 	 	 	 	 
	By:
	 	/s/ Raymond P. Warrell, Jr.	 	 	 	/s/ Gregg Siefert
	 
	 	 	 	 	 	 
	Name:
	 	Raymond P. Warrell, Jr.	 	 	 	 
	Title:
	 	Chairman & CEO	 	 	 	 

6

 

	 	 	 	 	 	 	 	 	 
	STATE OF New Jersey
	 	 	)	 	 	 	 	 
	 
	 	 	)	 	 	SS.:	 	 
	COUNTY OF Union
	 	 	)	 	 	 	 	 

     On this 28th day of May, 2008, before me personally appeared Illegible to me
known, who, being by me duly sworn, did depose and say that (s)he is the of GENTA INCORPORATED.,
the corporation described in and which executed the foregoing Amendment No. 3 to Lease; that (s)he knows the seal of said corporation, that the
seal affixed to said instrument is such corporate seal, that it was so affixed by authorization of the
board of directors of said corporation, and that (s)he signed his name thereto by like authorization.

     IN WITNESS WHEREOF, I hereunto set my hand and official seal.

	 	 	 	 	 
	 	 	 
	 	/s/ Janet
Pignio	 
	 	Notary Public 	 
	 	Commission Expires: 11/3/2012 	 
	 

(Notarial Seal)

	 	 	 	 	 	 	 	 	 
	STATE OF NEW JERSEY
	 	 	)	 	 	 	 	 
	 
	 	 	)	 	 	SS.:	 	 
	COUNTY OF UNION
	 	 	)	 	 	 	 	 

     On this 28th day of May, 2008, before me personally appeared Illegible to me known,
who, being by me duly sworn, did depose and say that (s)he is the Exec. VP of THE CONNELL
COMPANY, the corporation described in and which executed the foregoing Amendment No. 3 to
Lease; that (s)he knows the seal of said corporation, that the seal affixed to said instrument
is such corporate seal, that it was so affixed by authorization of the board of directors of
said corporation, and that (s)he signed his name thereto by like authorization.

     IN WITNESS WHEREOF, I hereunto set my hand and official seal.

	 	 	 	 	 
	 	 	 
	 	/s/ 
Christopher O. Jegede	 
	 	Notary Public 	 

	 	 	 
	 
	 	CHRISTOPHER O. JEGEDE
	(Notarial Seal)
	 	NOTARY PUBLIC OF NEW JERSEY
	 
	 	REGISTERED IN UNION COUNTY
	 
	 	MY COMMISSION EXPIRES JUNE 19, 2013

7

 

Schedule I

Fifth Floor Terminated Space

Fifth Floor

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]